Kabra Drugs PE ratio history and valuation
BSE: 524322Pharmaceuticals & BiotechnologySmall Cap
Kabra Drugs Ltd · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1993
Last close ₹15.86up ₹0.16 (1.02%)
Share price at the BSE close on 27 Oct 2026. Previous close ₹15.70.
27 Oct: open ₹15.50, high ₹16.50, low ₹15.50
52-week range of traded prices to 27 Oct 2026
₹15.50Low, 23 Oct 2026₹35.52High, 11 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹38 Cr3,225th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 4.95
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.27
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 28.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 28.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 74,044
Kabra Drugs' P/E, price to book, price to sales, EV to EBITDA, dividend yield and earnings yield on 27 Oct 2026, each against its own history of up to a year. The P/E is the market cap over the profit of the twelve months to Jun 2026.
Kabra Drugs PE ratio and valuation against its own history
- Price to earnings4.95today
1 year, since Nov 2025
Median 13.82Today is at or above 1% of the 235 days
- Price to book1.27today
1 year
Median 2.24Today is at or above 1% of the 247 days
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.0.29today
1 year
Median 1.06Today is at or above 1% of the 247 days
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.3.19today
1 year, since Nov 2025
Median 12.98Today is at or above 1% of the 235 days
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
1 year
Median 0.00%Today is at or above 100% of the 247 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.20.19%today
1 year
Median 7.05%Today is at or above 99.6% of the 247 days
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to earnings =Market cap÷Net profit, last twelve monthsNet profit, last twelve months. Net profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹7.59 Cr
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary₹30 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹132 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹0.43 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹11 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹8.60 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.2,37,07,850at 30 Sep 2026
Standalone accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Kabra Drugs financials ›
Kabra Drugs valuation at each year end
On the last trading day of each March, the month the company's year ends.
| Ratio | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 2.8 | 1.4 | 0.2 | 1.4 | 2.0 | 2.4 | 3.2 | 11.2 | 58.3 |
| Price to earnings | No full year | Loss | Profit not stated | Loss | Loss | Loss | Loss | Loss | 13.6 |
| Price to book | No balance sheet | No balance sheet | 1.3 | Negative net worth | Negative net worth | Negative net worth | Negative net worth | 3.4 | 2.2 |
| Price to sales | No full year | Revenue not stated | 24.6 | No revenue | No revenue | No revenue | No revenue | No revenue | 1.0 |
| EV to EBITDA | No full year | Operating profit not stated | Operating profit not stated | Operating loss | Operating loss | Operating loss | Operating loss | Operating loss | 12.7 |
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings yield | No full year | −60.7% | Profit not stated | −3.9% | −13.5% | −10.3% | −16.1% | −16.6% | 7.4% |
A ratio that does not exist on the day says why in its cell.
Kabra Drugs market cap, ten years
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Earnings per share, book value and enterprise value
From the close on 27 Oct 2026, with the last twelve months' results.
- Enterprise valueEnterprise value. Market cap plus borrowings less cash and bank balances: what it would cost to buy the whole business, its debts included.
- ₹27 Cr
- Earnings per shareEarnings per share, trailing. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) divided by the number of shares in issue.
- ₹3.20
- Book value per shareBook value per share. Net worth, the company's assets less everything it owes, divided by the number of shares in issue.
- ₹12.49
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹38 Cr
Against Pharmaceuticals
216 listed companies in Pharmaceuticals, each priced on its last trading day; Kabra Drugs is 182nd among them by market cap. Each median leaves out Kabra Drugs itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.5Across 158 other companies
- Listed companies with this P/E or lowerP/E among all listed companies. The share of the 3,398 listed companies with a trailing P/E on 27 Oct 2026 whose P/E is at or below Kabra Drugs'.
- 4%Of 3,398 companies with a P/E
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 3.0Across 190 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 20.0Across 146 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.50%Across 89 other companies
| Company | |||||
|---|---|---|---|---|---|
 Mangalam Drugs and OrganicsMANGALAM | 46 | – | 0.44 | – | 0.00% |
 Vasundhara RasayansVRL | 44 | 7.51 | 1.08 | 7.1 | 1.43% |
 ANG Lifesciences IndiaANG | 44 | – | 0.82 | – | 0.00% |
 Bharat Immunologicals & BiologicalsBIBCL | 40 | – | – | – | 0.00% |
| Kabra DrugsKABRADG | 38 | 4.95 | 1.27 | 3.2 | 0.00% |
 Medicamen OrganicsMEDIORG | 38 | – | – | – | 0.00% |
 Vista PharmaceuticalsVISTAPH | 36 | – | 1.00 | – | 0.00% |
 Rajnish WellnessRAJNISH | 35 | – | 0.34 | – | 0.00% |
 Jfl Life SciencesJFLLIFE | 34 | 4.99 | 0.74 | 4.6 | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.